Latest Administration News

The NSW Department of Planning and Environment has approved a six-year extension for the Dartbrook underground coal mine, pushing its operational horizon to 2033 despite ongoing financial administration challenges.

Island Pharmaceuticals has entered a pivotal research agreement with USAMRIID and the Geneva Foundation to accelerate FDA approval of Galidesivir for Marburg Virus Disease, leveraging top-tier US biodefense expertise.

ADX Energy has released an updated assessment of its Welchau well in Austria, revealing a significant increase in prospective gas-condensate and light oil resources. The 2024 drilling results highlight promising reservoir conditions and pave the way for further appraisal.

Avecho Biotechnology has completed recruitment for the interim analysis cohort of its pivotal Phase III trial for a CBD insomnia treatment, with results expected in June 2026. This milestone could significantly de-risk the program and unlock major market opportunities.

Eden Innovations Ltd reports a $1.43 million half-year profit, reversing prior losses thanks to a $4.45 million property sale and significant debt reduction, while advancing international commercialisation of its concrete and fuel technologies.

Platformo Ltd reported a modest 5% revenue increase in 2025 driven by its Malaysian subsidiary Biztrak, but faced a higher net loss due to regulatory delays and increased corporate advisory costs.

Peak Processing Limited reported a sharp 47.7% revenue drop and a 257.7% increase in losses for H1 2026, alongside a significant asset impairment and ongoing going concern concerns.

Recce Pharmaceuticals reported a doubling of its net loss for the half-year ended December 2025 amid significant progress in its anti-infective drug development and a substantial funding boost. The company is advancing Phase 3 trials and expanding its patent portfolio while managing financial pressures.

Epsilon Healthcare Limited has reported a robust recovery in 2025, with revenue climbing 68% to $9.39 million and net losses shrinking by 63%, driven by growth in contract manufacturing and a new pharmacy division.

Janus Electric Holdings reported a 46% increase in net loss to $4.93 million for the half-year ended December 2025, driven by rising costs despite a 33% revenue boost. The company faces funding uncertainties as it pursues key investments and operational scale-up.

1414 Degrees Ltd posted a steep 192% rise in half-year losses to $3.86 million, while advancing its silicon-based energy storage and hydrogen technologies. The company also faces uncertainty after its joint venture partner Vast Renewables entered administration.

Avecho Biotechnology reported a 9.3% revenue increase alongside a 41.5% rise in net loss for 2025, while progressing its Phase III CBD insomnia trial and securing a significant licensing agreement with Sandoz.